Chinese Dizal Pharma raises $100m from Lilly Asia, Sequoia, others

Chinese Dizal Pharma raises $100m from Lilly Asia, Sequoia, others

Dizal Pharmaceutical (Dizal Pharma) – a joint venture between state-owned SDIC Fund Management, Swedish drug maker AstraZeneca and Zytz Partners – has announced the completion of a $100-million  round of financing led by Lilly Asia Ventures (LAV). 

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter